# KalGene Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kalgene-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Candiac, Canada
- Website: www.kalgene.com
- Latest round: Series A (Nov 15, 2017)
- Investors on record: 3

## About

KalGene Pharmaceuticals Inc. is a biopharmaceutical company focused on innovative treatments for Alzheimer's disease, emphasizing cognitive function enhancement through its key product, KG207.Founded in 2007 in Candiac, Canada, KalGene Pharmaceuticals Inc. specializes in developing solutions for Alzheimer's patients. In November 2017, KalGene completed a Series A funding round led by Lumira Capital, attracting participation from investors such as Accel-Rx Health Sciences Accelerator and Anges Quebec. The company has raised a total of USD 1.50 mn from this funding round. The current CEO is Nickolay Kukekov.KalGene Inc. specializes in developing innovative solutions for Alzheimer's patients, with a focus on their flagship product, KG207. This product aims to enhance cognitive function and slow the progression of Alzheimer’s disease by targeting specific neurochemical pathways. KG207 has been designed following extensive research and clinical trials, addressing critical needs in the healthcare sector for effective Alzheimer’s treatments. The company serves a diverse client base that includes healthcare providers, research institutions, and patients directly affected by Alzheimer's. Geographically, Kalgene’s products are marketed primarily in North America and Europe, catering to a growing demand for specialized treatments in these regions.Kalgene Inc. generates revenue through a multi-faceted transaction structure that includes partnerships with healthcare providers and direct-to-consumer sales. Transactions often involve licensing agreements with hospitals and clinics that utilize KG207 as part of their treatment protocols for patients with Alzheimer's. Additionally, the company engages in collaborations with pharmaceutical distributors, ensuring that their products reach a wider audience. Pricing plans are structured to accommodate both institutional clients and individual consumers, reflecting the value of KG207 as a leading treatment option. The revenue model is supported by recurring purchases from healthcare facilities and ongoing consumer demand, solidifying Kalgene's position in the marketplace.KalGene Pharmaceuticals Inc. is focused on launching new products, including advancements to KG207, with the aim of enhancing its efficacy in treating Alzheimer's. The company plans to expand its market reach into Europe and Asia by 2022, targeting regions with a growing elderly population. Recent funding of USD 1.50 mn from the Series A round will be utilized to support these product developments and market expansions. This includes ongoing research and development efforts that are critical for addressing the evolving needs of Alzheimer's patients.

## Funding rounds

- Series A, Nov 15, 2017 — Anges Quebec, Accel-Rx Health Sciences Accelerator, Lumira Ventures

## Investors

- Anges Quebec — Series A
- Accel-Rx Health Sciences Accelerator — Series A
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A